Biocon Limited

BIOCON

INE376G01013

Biotechnology & Medical Research

Market Closed - NSE India S.E. Other stock markets 07:40:47 2024-04-29 EDT			5-day change	1st Jan Change
306.2 ^INR	-0.08%		+12.91%	+22.63%

04-20	Biocon Limited Receives Approval from the South African Health Products Regulatory Authority for its Vertically Integrated, Complex Drug Product Tacrolimus Capsule 0.5mg, 1mg and 5mg Strengths, in South Africa	CI
04-18	India's Biocon developing its own version of Wegovy, clinical trial likely next year	RE

Biocon Limited Announces Revenue Guidance for the Full Financial Year 2022

October 21, 2021 at 02:11 pm

Biocon Limited announced revenue guidance for the full financial year 2022. For the period, the company anticipates mid-teens revenue growth.

Latest news about Biocon Limited

Biocon Limited Receives Approval from the South African Health Products Regulatory Authority for its Vertically Integrated, Complex Drug Product Tacrolimus Capsule 0.5mg, 1mg and 5mg Strengths, in South Africa	04-20	CI
India's Biocon developing its own version of Wegovy, clinical trial likely next year	04-18	RE
Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil	04-17	MT
Biocon Limited Signs an Exclusive Licensing and Supply Agreement with Biomm S.A	04-17	CI
Biocon Board to Consider Dividend for Fiscal 2024	04-10	MT
Eris Lifesciences Completes Acquisition of Biocon Biologics' India Formulation Business	04-02	MT
Biocon Limited, Through Zentiva, Receives Approval from, U.K., for its Complex Formulation Liraglutide (gSaxenda®) in 6mg/ml Solution	03-31	CI
Biocon Limited to Obtain Approval for Diabetes Drug, Liraglutide, in the U.K	03-27	CI
Biocon Limited Receives an Order from the Reserve Bank of India	03-22	CI
Eris Lifesciences to Acquire India Formulation Business of Biocon Biologics for INR12.42 Billion	03-15	MT
Biocon's CFO Resigns	03-14	MT
Biocon Limited Accepts Resignation of Indranil Sen as Chief Financial Officer	03-14	CI
Eris to Acquire Additional Stake in Swiss Parenterals, Take Over Branded Formulations Business of Biocon Biologics	03-14	MT
India's Biocon to sell branded formulations business to Eris Lifesciences for $150 million	03-14	RE
Biocon Limited Announces Executive Appointments	03-04	CI
Biocon Arm to Launch Colorectal Cancer Biosimilar in Canada	03-04	MT
Bristol Myers CEO says India to have largest R&D presence outside US by 2025	02-27	RE
INDIA STOCKS-Indian shares muted after five-session rally, tracking Asian peers	02-19	RE
Jefferies Adjusts Biocon’s Price Target to INR250 From INR255, Keeps at Hold	02-12	MT
Biocon Swings to Profit in Fiscal Q3	02-09	MT
Transcript : Biocon Limited, Q3 2024 Earnings Call, Feb 09, 2024	02-08
Indian shares set for a muted start, tracking Asian peers	02-08	RE
Biocon CFO Resigns	02-08	MT
India's Biocon posts profit on biosimilar boost, divestment gains; CFO resigns	02-08	RE
Biocon Limited Announces Indranil Sen Resigns as Chief Financial Officer, Effective March 15, 2024	02-08	CI

Biocon Limited is an India-based biopharmaceutical company, which focuses on treating diabetes, cancer and autoimmune diseases. Its segment includes Generics, Biosimilars, Novel Biologics and Research Services. It has developed and commercialized novel biologics, biosimilars, and complex small molecule active pharmaceutical ingredients (APIs) in India and several key global markets, as well as Generic Formulations in the United Sates, Europe and key emerging markets. Its API portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology and other key products. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. It has over five facilities across Bangalore, Hyderabad and Visakhapatnam in India. Its API manufacturing facilities leverage complex technology platforms that range from microbial fermentation, chromatographic purification, chemical synthesis, peptide synthesis and HPAPIs.

Sector

Biotechnology & Medical Research

Calendar

2024-05-15 - Q4 2024 Earnings Release

Related indices

NIFTY 100

More about the company

Income Statement Evolution

More financial data

Ratings for Biocon Limited

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

306.2 INR

Average target price

279.1 INR

Spread / Average Target

-8.83%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOCON LIMITED	+22.63%	4.39B
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	103B
REGENERON PHARMACEUTICALS, INC.	+1.62%	95.28B
ARGENX SE	+1.46%	22.15B
BIONTECH SE	-16.67%	21.02B
GENMAB A/S	-8.58%	18.15B
WUXI APPTEC CO., LTD.	-38.74%	16.73B
BEIGENE, LTD.	-13.21%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B

Bio Therapeutic Drugs

Biocon Limited

Equities

BIOCON

INE376G01013

Biotechnology & Medical Research

Biocon Limited Announces Revenue Guidance for the Full Financial Year 2022

Latest news about Biocon Limited

Chart Biocon Limited

Company Profile

Income Statement Evolution

Ratings for Biocon Limited

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs